Shielding of lipid nanoparticles for siRNA delivery: Impact on physicochemical properties, cytokine induction, and efficacy

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages e210-

  Kumar, Varun ^a   Qin, June ^a   Jiang, Yongfeng ^a   Duncan, Richard G ^a   Brigham, Benjamin ^a   Fishman, Shannon ^a   Nair, Jayaprakash K ^a   Akinc, Akin ^a   Barros, Scott A ^a   Kasperkovitz, Pia V ^a  

^a ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

Delivery; Immune response; Nanomedicine; Nanoparticles; Polyethylene glycol; RNAi

Indexed keywords

APOLIPOPROTEIN E; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KERATINOCYTE DERIVED CHEMOKINE; LIGAND; MACROGOL; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DENSITY; DRUG EFFICACY; ERYTHROCYTE; GEL PERMEATION CHROMATOGRAPHY; GENE DELIVERY SYSTEM; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LIPID COMPOSITION; LIVER CELL; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTON TRANSPORT; STATIC ELECTRICITY; SURFACE CHARGE; ZETA POTENTIAL;

EID: 84925271705     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.61     Document Type: Article

References (40)

1. Coelho, T, Adams, D, Silva, A, Lozeron, P, Hawkins, PN, Mant, T et al. (2013). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369: 819-829.
2. Fitzgerald, K, Frank-Kamenetsky, M, Shulga-Morskaya, S, Liebow, A, Bettencourt, BR, Sutherland, JE et al. (2014). Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383: 60-68.
3. Medzhitov, R and Janeway, CA Jr (1997). Innate immunity: the virtues of a nonclonal system of recognition. Cell 91: 295-298.
4. Iwasaki, A and Medzhitov, R (2010). Regulation of adaptive immunity by the innate immune system. Science 327: 291-295.
5. Szebeni, J (2005). Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216: 106-121.
6. Immordino, ML, Dosio, F and Cattel, L (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1: 297-315.
7. Gref, R, Minamitake, Y, Peracchia, MT, Trubetskoy, V, Torchilin, V and Langer, R (1994). Biodegradable long-circulating polymeric nanospheres. Science 263: 1600-1603.
8. Lasic, DD, Martin, FJ, Gabizon, A, Huang, SK and Papahadjopoulos, D (1991). Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070: 187-192.
9. Torchilin, VP and Trubetskoy, VS (1995). Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Delivery Rev 16: 141-155.
10. Illum, L and Davis, SS (1984). The organ uptake of intravenously administered colloidal particles can be altered using a non-ionic surfactant (Poloxamer 338). FEBS Lett 167: 79-82.
11. Illum, L and Davis, SS (1987). Targeting of colloidal particles to the bone marrow. Life Sci 40: 1553-1560.
12. Akerman, ME, Chan, WC, Laakkonen, P, Bhatia, SN and Ruoslahti, E (2002). Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 99: 12617-12621.
13. Gref, R, Lück, M, Quellec, P, Marchand, M, Dellacherie, E, Harnisch, S et al. (2000). 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 18: 301-313.
14. Walkey, CD, Olsen, JB, Guo, H, Emili, A and Chan, WC (2012). Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc 134: 2139-2147.
15. Leroux, JC, De Jaeghere, F, Anner, B, Doelker, E and Gurny, R (1995). An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. Life Sci 57: 695-703.
16. Norman, ME, Williams, P and Illum, L (1993). Influence of block copolymers on the adsorption of plasma proteins to microspheres. Biomaterials 14: 193-202.
17. Moghimi, SM and Szebeni, J (2003). Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42: 463-478.
18. Bradley, AJ, Devine, DV, Ansell, SM, Janzen, J and Brooks, DE (1998). Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. Arch Biochem Biophys 357: 185-194.
19. Perry, JL, Reuter, KG, Kai, MP, Herlihy, KP, Jones, SW, Luft, JC et al. (2012). PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett 12: 5304-5310.
20. Whitehead, KA, Dahlman, JE, Langer, RS and Anderson, DG (2011). Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng 2: 77-96.
21. Coch, C, Lück, C, Schwickart, A, Putschli, B, Renn, M, Höller, T et al. (2013). A human in vitro whole blood assay to predict the systemic cytokine response to therapeutic oligonucleotides including siRNA. PLoS One 8: e71057.
22. Robbins, M, Judge, A, Liang, L, McClintock, K, Yaworski, E and MacLachlan, I (2007). 2′-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther 15: 1663-1669.
23. Fucini, RV, Haringsma, HJ, Deng, P, Flanagan, WM and Willingham, AT (2012). Adenosine modification may be preferred for reducing siRNA immune stimulation. Nucleic Acid Ther 22: 205-210.
24. Barros, SA and Gollob, JA (2012). Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev 64: 1730-1737.
25. Abrams, MT, Koser, ML, Seitzer, J, Williams, SC, DiPietro, MA, Wang, W et al. (2010). Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther 18: 171-180.
26. Bao, Y, Jin, Y, Chivukula, P, Zhang, J, Liu, Y, Liu, J et al. (2013). Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes. Pharm Res 30: 342-351.
27. Semple, SC, Klimuk, SK, Harasym, TO, Dos Santos, N, Ansell, SM, Wong, KF et al. (2001). Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510: 152-166.
28. Maurer, N, Wong, KF, Stark, H, Louie, L, McIntosh, D, Wong, T et al. (2001). Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J 80: 2310-2326.
29. Hafez, IM, Maurer, N and Cullis, PR (2001). On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 8: 1188-1196.
30. Jayaraman, M, Ansell, SM, Mui, BL, Tam, YK, Chen, J, Du, X et al. (2012). Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 51: 8529-8533.
31. Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18: 1357-1364.
32. Heyes, J, Palmer, L, Bremner, K and MacLachlan, I (2005). Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 107: 276-287.
33. Murthy, N, Robichaud, JR, Tirrell, DA, Stayton, PS and Hoffman, AS (1999). The design and synthesis of polymers for eukaryotic membrane disruption. J Control Release 61: 137-143.
34. Sato, Y, Hatakeyama, H, Sakurai, Y, Hyodo, M, Akita, H and Harashima, H (2012). A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J Control Release 163: 267-276.
35. Pham, CT, Thomas, DG, Beiser, J, Mitchell, LM, Huang, JL, Senpan, A et al. (2014). Application of a hemolysis assay for analysis of complement activation by perfluorocarbon nanoparticles. Nanomedicine 10: 651-660.
36. Kuznetsova, NR, Sevrin, C, Lespineux, D, Bovin, NV, Vodovozova, EL, Mészáros, T et al. (2012). Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer. J Control Release 160: 394-400.
37. Judge, AD, Bola, G, Lee, AC and MacLachlan, I (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13: 494-505.
38. Seki, S, Habu, Y, Kawamura, T, Takeda, K, Dobashi, H, Ohkawa, T et al. (2000). The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol Rev 174: 35-46.
39. Akinc, A, Goldberg, M, Qin, J, Dorkin, JR, Gamba-Vitalo, C, Maier, M et al. (2009). Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 17: 872-879.
40. Mui, BL, Tam, YK, Jayaraman, M, Ansell, SM, Du, X, Tam, YY et al. (2013). Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. Mol Ther Nucleic Acids 2: e139.